Trial Profile
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Aug 2019
Price :
$35
*
At a glance
- Drugs Vonapanitase (Primary)
- Indications Vascular disorders
- Focus Registrational; Therapeutic Use
- Acronyms PATENCY-2
- Sponsors Proteon Therapeutics
- 20 Jul 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2019 Planned End Date changed from 1 Jun 2018 to NULL.
- 28 Mar 2019 Results presented in a Proteon Therapeutics Media Release.